Denali Therapeutics


Denali Therapeutics is a biopharmaceutical company focused on developing biologic medicines that cross the blood–brain barrier to treat neurodegenerative diseases, lysosomal storage disorders and other serious conditions. The company develops a platform for systemic delivery of enzymes, oligonucleotides and antibodies to the central nervous system, advances translational research published in peer-reviewed journals, maintains biologics manufacturing and clinical supply capabilities, and pursues collaborations with industry, academia and patient communities.

Industries

Biotechnology
Genetics
Health Diagnostics
Therapeutics
Healthcare Services & Hospitals
Healthcare
Biotechnology Research

Nr. of Employees

large (251-1000)

Denali Therapeutics

South San Francisco, California, United States


Patents

Compounds, compositions, and methods

US-12747232-B2

View Details

Anti-HER2 antibodies and methods of use thereof

US-12703761-B2

View Details

Formulations of protein molecules comprising iduronate 2-sulfatase

US-12667606-B2

View Details

Solid forms of a compound

US-12662458-B2

View Details

Anti-transferrin receptor fusion proteins and methods of use thereof

US-12636363-B2

View Details

Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

US-12497387-B2

View Details
View All Patents

Products

AVLAYAH (tividenofusp alfa-eknm)

Registered therapeutic referenced with prescribing information and assigned a permanent J-code (J1757).


Services

Structured collaborations with industry, academic institutions, foundations and enabling technology partners to advance discovery, development and commercialization.

Engagement with patient communities and provision of information about clinical studies and enrollment to support trial conduct and incorporate real-world perspectives.

Expertise Areas

  • CNS delivery platform development
  • Lysosomal storage disorder therapeutics
  • Neurodegenerative disease therapeutics
  • Biologics process development and scale-up
  • Show More (4)

Key Technologies

  • Blood–brain barrier transport platforms
  • Transferrin receptor–mediated targeting
  • Enzyme replacement therapy for CNS and somatic disease
  • Antisense oligonucleotide CNS delivery
  • Show More (4)

News & Updates

Peer-reviewed article reporting an intravenous brain-penetrant enzyme therapy in The New England Journal of Medicine.

Science article describing transferrin receptor–targeted antibody approaches to improve brain delivery and mitigate ARIA.

Science Translational Medicine article on transferrin receptor targeting to enable antisense oligonucleotide transport across the blood–brain barrier.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.